| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6579968 | PALATIN TECHNOLOGIES | Compositions and methods for treatment of sexual dysfunction |
Jun, 2021
(2 years ago) | |
| US6794489 | PALATIN TECHNOLOGIES | Compositions and methods for treatment of sexual dysfunction |
Jun, 2025
(1 year, 2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9352013 | PALATIN TECHNOLOGIES | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(9 years from now) | |
| US10286034 | PALATIN TECHNOLOGIES | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(9 years from now) | |
| US9700592 | PALATIN TECHNOLOGIES | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(9 years from now) | |
| US11590209 | PALATIN TECHNOLOGIES | Use of bremelanotide in patients with controlled hypertension |
Apr, 2041
(17 years from now) | |
Vyleesi (Autoinjector) is owned by Palatin Technologies.
Vyleesi (Autoinjector) contains Bremelanotide Acetate.
Vyleesi (Autoinjector) has a total of 6 drug patents out of which 1 drug patent has expired.
Expired drug patents of Vyleesi (Autoinjector) are:
- US6579968
Vyleesi (Autoinjector) was authorised for market use on 21 June, 2019.
Vyleesi (Autoinjector) is available in solution;subcutaneous dosage forms.
Vyleesi (Autoinjector) can be used as treatment of hypoactive sexual desire disorder (hsdd), treating acquired, generalized hypoactive sexual desire disorder (hsdd) in a premenopausal female patient with controlled hypertension by injecting bremelanotide more than once with at least 24 hours between doses and no more than 8 doses per month.
Drug patent challenges can be filed against Vyleesi (Autoinjector) from 22 June, 2023.
The generics of Vyleesi (Autoinjector) are possible to be released after 29 April, 2041.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 21, 2024 |
Drugs and Companies using BREMELANOTIDE ACETATE ingredient
NCE-1 date: 22 June, 2023
Market Authorisation Date: 21 June, 2019
Treatment: Treatment of hypoactive sexual desire disorder (hsdd); Treating acquired, generalized hypoactive sexual desire disorder (hsdd) in a premenopausal female patient with controlled hypertension by injecti...
Dosage: SOLUTION;SUBCUTANEOUS
VYLEESI (AUTOINJECTOR) family patents
